Evidence map›Paper›PMID 41282937›Full record

ArticlemedRxiv : the preprint server for health sciences2025

PERFORMANCE OF FUJILAM VERSION 1 FOR THE DIAGNOSIS OF TUBERCULOSIS IN CHILDREN UNDER 5 YEARS IN UGANDA - A BRIEF REPORT.

Mirembe Angella Nanteza, Nelson Mukiza, Freddie Bwanga, Victor Musiime, Grace Paul Kisitu, Nathan Mudrak, Nisreen Khambati, Germine Nakayita, Emmanuel Nasinghe, Prossy Mbekeka and 14 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Mirembe Angella NantezaDepartment of Paediatrics, College of Health Sciences, Makerere University, Kampala, Uganda.
Nelson MukizaRineCynth Advisory Limited, Kampala, Uganda.
Freddie BwangaDepartment of Paediatrics, College of Health Sciences, Makerere University, Kampala, Uganda.
Victor MusiimeDepartment of Paediatrics, College of Health Sciences, Makerere University, Kampala, Uganda.
Grace Paul KisituBaylor College of Medicine Children's Foundation-Uganda, Kampala, Uganda.
Nathan MudrakOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Nisreen KhambatiOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Germine NakayitaDepartment of Immunology and Molecular Biology, College of Health Sciences, Makerere University, Kampala, Uganda & Integrated Biorepository of the H3Africa Uganda, Kampala, Uganda.
Emmanuel NasingheDepartment of Immunology and Molecular Biology, College of Health Sciences, Makerere University, Kampala, Uganda & Integrated Biorepository of the H3Africa Uganda, Kampala, Uganda.
Prossy MbekekaJinja Regional Referral/Nalufenya Children's Hospital (Jinja, Uganda).
Rudie DesravinesFrontier Science Foundation, Brookline, MA, USA.
Rutvi UpadhyayDivision of Infectious Diseases, Center for Emerging Pathogens, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Emily DouglassDivision of Infectious Diseases, Center for Emerging Pathogens, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Adeodata R KekitiinwaBaylor College of Medicine Children's Foundation-Uganda, Kampala, Uganda.
Jerrold J EllnerDivision of Infectious Diseases, Center for Emerging Pathogens, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Susan E DormanMedical University of South Carolina, Charleston, SC, USA.
Adam Penn-NicholsonFIND, Geneva, Switzerland.
Soyeon KimFrontier Science Foundation, Brookline, MA, USA.
David AllandPublic Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Padmini SalgameDivision of Infectious Diseases, Center for Emerging Pathogens, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Rinn SongOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Francesca Wanda BasileOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Moses JolobaDepartment of Immunology and Molecular Biology, College of Health Sciences, Makerere University, Kampala, Uganda & Integrated Biorepository of the H3Africa Uganda, Kampala, Uganda.
Else Margreet BijkerOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

Funding

FEND for TB supplement to accelerate BLINK X developmentU01AI152084 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, DORMAN, SUSAN E · 2020 to 2024
$20.0M
Novel and Optimized Diagnostics for Pediatric TBR01AI152159 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, ELLNER, JERROLD J. · 2020 to 2024
$6.0M
NIAID NIH HHS R01 AI152159NIAID NIH HHS U01 AI152084
6 · The paper itself

Abstract

Background: Diagnosing tuberculosis in children remains challenging due to the paucibacillary nature of the disease, non-specific symptoms, and difficulty collecting samples. New tests are urgently needed. We evaluated the diagnostic accuracy of FujiLAM version 1 urine test in children under 5 years with presumptive tuberculosis in Uganda. Methods: This was a cross-sectional evaluation nested in the NOD-pedFEND diagnostic study. Children under 5 years with signs or symptoms of tuberculosis were recruited from three hospitals in Uganda. All participants underwent comprehensive baseline investigations, including culture and Xpert MTB/RIF Ultra on reference samples and chest X-ray. Culture and Xpert MTB/RIF Ultra results were used to define a microbiological reference standard. FujiLAM version 1 testing was performed on fresh urine at the baseline visit. Results: Seventy-nine children were included in the study. Fifteen participants (19%) were classified as having microbiologically confirmed TB, 44 (56%) as unconfirmed TB, thirteen (16%) as unlikely TB, and seven participants (9%) were unclassifiable. Only one participant (with unlikely TB) had a positive FujiLAM test. Culture and Xpert MTB/RIF Ultra on reference samples were negative in this child, indicating poor diagnostic accuracy with a sensitivity of 0% (95% CI: 0 - 21.8) of FujiLAM version 1 against the microbiological reference standard. Conclusion: The poor diagnostic accuracy of FujiLAM version 1 in children under five years of age makes it unsuitable as a diagnostic test in this age group. Further evaluation with the optimized version 2 of this test is needed.

Indexed as

childrendiagnostic accuracydiagnostic performanceFujiLAMtuberculosisurine

Identifiers

PMID41282937
PMCPMC12633152

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.